… Therefore, we propose that a drug discovery program should pursue an optimisation trajectory
towards compounds belonging to k-means cluster 2 falling on bottom-left quadrant I of the …

… design (SBDD), and medicinal chemistry efforts targeting cysteine proteases in Chagas
disease and HAT drug discovery will be discussed. Structural aspects of enzyme-inhibitor …

… Drug development for tropical diseases has largely relied on three strategies: label extension,
piggyback discovery, and de novo drug discovery. Label extension consists of extending …

… As with other neglected diseases, the current drug therapy for Chagas Disease has many
drawbacks. Two drugs are routinely used, benznidazole and nifurtimox (Figure 3). As noted by …

… explain why treatment so often fails to cure Chagas disease [14]. Thus, many efforts … Chagas
disease. Several experts in the drug discovery field and the Drugs for Neglected Diseases …

… Top series of xanthine have been recently identified as clinical candidate for Chagas disease…
Conclusion: In summary, loans on anti-Chagas disease agents focused to specific parasite …

… GNF7686 represents a promising starting point for Chagas disease drug discovery as it
potently inhibits growth of intracellular T. cruzi amastigotes with a half maximal effective …

… cruzi biomarker in blood and validate murine drug discovery models of Chagas disease. In
two … They suggest that the ELA assay can be used in drug discovery applications to assess …

… treating the chronic phase of Chagas disease, ML341 is an attractive starting point for
developing drugs against both acute and chronic stages of Chagas disease. Results from further …

… for drug discovery is to reposition drugs from other disease … need to refine the drug discovery
pathway for Chagas disease, in … made in drug discovery to find potential new drugs to treat …